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HIV-1 and HTLV-1 can infect CD4+ T cells and can co-infect the same individual. In principle, it is possible
that both viruses can infect the same CD4+ T cells in dually infected persons. Currently, how efﬁciently
HTLV-1 and HIV-1 co-infects the same cell and the full extent of their biological interactions are not well-
understood. Here, we report evidence conﬁrming that both viruses can infect the same cells and that
HTLV-1 envelope (Env) can pseudotype HIV-1 viral particles and HIV-1 envelope (Env) can pseudotype
HTLV-1 virions to mediate subsequent infections of substrate cells. We also show that the construction of
a chimeric HTLV-1 molecular clone carrying the HIV-1 Env in place of its HTLV-1 counterpart results in a
replication competent moiety. These ﬁndings raise new implications of viral complementation and
assortment between HIV-1 and HTLV-1 in dually infected persons.
Published by Elsevier Inc.Introduction
Human T-cell Leukemia Virus (HTLV-1) and Human Immunode-
ﬁciency Virus (HIV-1) are the two known pathogenic human retro-
viruses (Gallo, 2005). Worldwide, approximately 20 million people
are infected with HTLV-1 (Proietti et al., 2005). Infection by HTLV-1 is
associated with the development of Adult T-cell Leukemia (ATL) in a
minority of individuals following a lengthy latency period (20–40
years). HTLV-1 infection with is also associated with inﬂammatory
diseases such as HTLV-1 Associated Myelopathy/ Tropical Spastic
Paraparesis (HAM/TSP) (Gessain and Mahieux, 2012).
HIV-1 infection leads to an acute phase of infection lasting
several weeks that is characterized by a high plasma viral load.
Following the acute period, levels of HIV-1 in the blood drop to a set
point that characterizes chronic infection (Fauci et al., 1996). Over
time the infected person's CD4+ T-cell count decreases and, in the
absence of therapy, most individuals acquire opportunistic infec-
tions that usually progress to death (Fauci et al., 1996). The HIV-1
envelope (Env) binds the CD4 receptor (Wilen et al., 2012), while
the receptor for HTLV-1 remains controversial (Ghez et al., 2006; Jin
et al., 2006; Manel et al., 2003; Pinon et al., 2003). However, the
virus is known to be capable of infecting CD4+ and CD8+ T cells
(Eiraku et al., 1998; Jones et al., 2008; Manel et al., 2005).
HIV-1 infected individuals can be co-infected with a variety of
other viruses. Several studies have reported co-infection of HIV-1
with herpesviruses (da Silva and de Oliveira, 2011), hepatitis B
virus (HBV) (Martin-Carbonero and Poveda, 2012), hepatitis CInc.virus (HCV) (Taylor et al., 2012) and other viruses. In each of these
examples, while the host is infected with multiple viruses,
individual cells are infected with only one virus due to tropism.
Thus, in such co-infections, the different viral genomes and their
gene products are unlikely to co-exist or interact within the
same cells.
HIV-1 and HTLV-1 co-infection in vivo has also been extensively
reported, and it has been suggested that co-infection by the two
viruses inﬂuences the pathologic progression of both viruses (Bahia
et al., 2011; Beilke, 2012; Brites et al., 2009; Pedroso et al., 2011).
Because both HIV-1 and HTLV-1 can infect CD4+ T cells, this co-
infection may differ from those of HIV-1/herpesviruses in that both
viral genomes could co-exist in a single infected cell. Although
several labs have examined co-infection at the cellular level
(Monteﬁori and Mitchell, 1987; Spear et al., 1991; Szabo et al.,
1999), these analyses report either very rare cases of co-infection
or rely on the developmental of a cell line stably infected with either
HIV-1 or HTLV-1. A clone of this stable infection is then expanded
and infected with the other virus. Herein, we re-examined the issue
and demonstrated de novo co-infection of the same cell using ﬂow
cytometry. We found that co-infection can lead to psuedotyping of
the HIV-1 virion with HTLV-1 Env. To examine the reciprocal nature
of pseudotyping, we also created a chimeric HTLV-1 that carries the
HIV-1, but not the HTLV-1, Env. We demonstrated that this virus can
competently replicate and compete with WT HIV-1 in a spreading
viral replication.
Super infection exclusion describes the property of virally
infected cells to be resistant to re-infection (super infection) with
a new incoming virion (Nethe et al., 2005; Potash and Volsky,
1998). (1;2) Super infection exclusion has been described for a
variety of human viral diseases including; inﬂuenza A, Rubella,
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viruses and HIV-1 (Berg et al., 2003; Bock et al., 1998; Claus
et al., 2007; Giannecchini et al., 2007; Lee et al., 2005; Mador et al.,
2002; Nethe et al., 2005; Tscherne et al., 2007; Turner and Moyer,
2008; Whitaker-Dowling et al., 1983). In HIV-1 infection Nef, Env
and Vpu down regulate cell surface expression of the CD4 receptor
molecule (Nethe et al., 2005; Wildum et al., 2006). Binding of Nef
to CD4 and a set of multiple adapter proteins leads to endocytosis
and degradation of CD4 (Lindwasser et al., 2007; Rose et al., 2005).
In contrast to Nef, Env and Vpu work to prevent transport of newly
synthesized CD4 molecules to the cell surface (Lindwasser et al.,
2007; Wildum et al., 2006). The ability of our HTLV-1 chimera to
inhibit HIV-1 replication suggests that Env alone may be sufﬁcient
to mediate super-infection exclusion.Results
HTLV-1 and HIV-1 infect the same cell
To examine HTLV-1 and HIV-1 infection of the same cell, we
employed the J-LTR-G reporter cell line (Kutsch et al., 2004) and
antibody speciﬁc to HTLV-1 Env gp46. J-LTR-G is a Jurkat T-cell line
that carries an HIV-1 LTR driving a GFP reporter; GFP is produced
when this cell line is infected with HIV-1. For our experiments,
J-LTR-G cells were cultured alone (Fig. 1A, ﬁrst panel), with HIV-1
NL4-3 (Fig. 1A, second panel), with HTLV-1 transformed virus-
producer cell line MT2 (Fig. 1A, third panel), or with HTLV-1
transformed virus-producer cell line MT2 and HIV-1 NL4-3
(Fig. 1A, fourth panel). Uninfected J-LTR-G cells showed background
staining for gp46 and a background level of GFP (Fig. 1A, ﬁrst panel).
Co-culture of J-LTR-G with MT2 resulted in the detection of cells
positively stained for HTLV-1 gp46 (Fig. 1, second panel). The ﬂow
cytometric proﬁle shows two populations with the MT2 cells
distinguishable as a brightly stained smaller discrete cell population
(red arrow) while the gp46 positive J-LTR-G cells are represented by
a rightward shifted larger cell population (black arrow). The
rightward-shift of the J-LTR-G population along the gp46 staining
axis is consistent with HTLV-1 virions produced from MT2 cells
successfully infecting the former cells. Infection of J-LTR-G with
HIV-1 NL4-3 produced, as expected, a population of GFP positive
cells (12.6%; Fig. 1A third panel), and the co-culture of J-LTR-G with
MT2 and HIV-1 NL4-3 produced cell populations that are positive
for both gp46 and GFP (39.7%; Fig. 1A fourth panel). The latter cells
(39.7% GFP+gp46+) represent cells that are simultaneously infected
with both HTLV-1 and HIV-1. An interesting observation from this
experiment was that co-infection with HTLV-1 increased the
number of GFP (HIV-1) positive cells. To insure that this was not
an artifact, a follow-up experiment was performed in the setting of
spreading infection that also indicated that infection with HTLV-1
could increase HIV-1 replication (Supplemental Fig. S1).
To conﬁrm the above results in a different system we chose to
examine co-infection by ﬂuorescent microscopy. In brief, Jurkat T-cells
were placed in the bottom section of a transwell tissue culture plate.
PMA stimulated ACH2 and MT-2 cells were placed in the upper well
and the cultured carried for 72 h. Jurkat T-cells were then afﬁxed to a
slide and stained for HTLV-1 Tax or HIV-1 Envelope (Fig. 1B). This
staining conﬁrmed the results of the ﬂow cytometry, in that unin-
fected, singly infected and doubly infected cells were all found in the
same culture.
Co-infection generates HIV-1 virions pseudotyped by the HTLV-1 Env.
We next asked if co-infection of a cell by HIV-1 and HTLV-1
could lead to pseudotyping of the former by the latter envelope
protein. Because an HIV-1 virion carrying an HTLV-1 envelopecould allow the broader HIV-1 tropism, we ﬁrst examined HIV-1
pseudotyping by the HTLV-1 envelope (Fig. 2). Accordingly, we
prepared VSV-G pseudotyped HIV-1 particles by co-transfecting a
VSV-G expression vector and an envelope-deleted NL4-3 ΔEnv GFP
(Zhang et al., 2004) molecular clone into 293 T cells. Supernatant
containing VSV-G pseudotyped HIV-1 virions was harvested from
the 293 T cells 48 h after transfection and ﬁltered; the ﬁltrate was
used to infect either Jurkat or MT2 cells. Three days later, the
infected Jurkat or MT2 cells were separately co-cultured with the
HIV-1 indicator cell line TZMbl. We expected that the envelope-
deleted NL4-3 ΔEnv GFP genome would not produce infectious
particles in Jurkat cells because these cells express no retroviral
Env protein. On the other hand because MT2 cells do express
HTLV-1 Env protein (Harada et al., 1985). Should this envelope
protein be competent for pseudotyping HIV-1, then HTLV-1 Env
pseudotyped HIV-1 particles should be produced. In that setting,
HTLV-1 Env pseudotyped HIV-1 virions could be detected by an
infection assay using TZMbl cells. Indeed, β-galactosidase staining
of a co-culture of NL4-3 ΔEnv GFP/MT2 with TZMbl cells shows
positive staining. The control co-culture of NL4-3 ΔEnv GFP/Jurkat
with TZMbl does not (Fig. 2A, B).
To further verify that the results from co-culture of NL4-3 ΔEnv
GFP/MT2 with TZMbl cells were due to pseudotyping of NL4-3
ΔEnv GFP with the HTLV-1 Env from MT2, we repeated the co-
culturing assay in the presence of neutralizing antibodies speciﬁc
for HIV-1 or HTLV-1 envelope proteins (Fig. 2C). In the presence of
anti-HTLV-1 antibody, a dose-dependent inhibition of TZMbl
reporter readout was seen, while in the presence of anti-HIV-1
antibody a small change could be observed only at the highest
antibody concentration. These results support the interpretation
that infectious NL4-3 ΔEnv GFP virions arise after pseudotyping by
HTLV-1 Env protein.
Construction of a chimeric HTLV-1 genome that expresses
HIV-1 envelope
We took a different approach to investigate whether HTLV-1
could be pseudotyped with HIV-1 Env. Using the HTLV-1 ACH
molecular clone (Kimata et al., 1994), we created a chimeric HTLV-
1 genome in which the native Env gene was replaced with the
HIV-1 Env gene from the NL4-3 molecular clone (Fig. 3).
We reasoned that if HIV-1 Env could complement HTLV-1 Env
function, then this chimeric HTLV-1 genome should be replication
competent. In our chimera, we modeled our cloning strategy after
that performed by Delebecque et al. (2005, 2002). in which the
HTLV-I Env in a molecular clone was replaced by a heterologous
Env gene from MuMLV. In order not to perturb the splicing and
processing of the HTLV-I genome, the signal peptide from the
HTLV-1 Env gene was fused to the NL4-3 HIV-1 Env resulting in a
modiﬁed Env whereby the signal peptide of HIV-1 Env was
replaced with the HTLV-I signal peptide. This chimeric Env was
then inserted back into the ACH molecular clone using the SphI
and NsiI restriction sites (Fig. 3A). Although this construct will not
express HIV-1 Rev, the HTLV-1 Rex coding sequence remains un-
perturbed. Rex has been shown to be capable of stabilizing HIV-1
Env, complementing Rev function and will allow expression in this
chimera (Hanly et al., 1989).
We next determined if the pACH-Chimera proviral genome
could express HIV-1 Env. TZMbl cells were transfected separately
with increasing amounts of pACH or pACH-Chimera, or with a
pCMV 4-3 Env expression vector as control (Fig. 3B). Western
blotting using human HIV-1 hyper-immune serum showed that
increasing the transfection of pACH-Chimera led to increasing
expression of Env protein in the TZMbl cells (Fig. 3B, lanes 6–8)
which co-migrated with envelope protein produced from trans-
fected pCMV 4-3 Env expression vector (Fig. 3B, lane 1). In contrast
Fig. 1. HIV-1 and HTLV-1 are capable of de novo infection of the same target cell. (A) Jurkat indicator cells (J-LTR-G) were infected with NL4-3 HIV-1 viral stocks. Four days
post HIV-1 infection the cells were co-cultured 10:1 with HTLV-1 infected cell line MT2. After three days of co-culture infection was detected by ﬂow cytometry for GFP
(HIV-1) or cell surface gp46 (HTLV-1) using an AlexaFluor547 conjugated anti-gp46. Black arrow indicates HTLV infected J-LTR-G cells, while the red arrow indicates the MT-2
cells from co-culture. (B) Jurkat cells were placed in the bottomwell of a transwell plate. ACH2 and MT2 cells were stimulated with 1 μm PMA for twenty-four hours, washed
and placed in the top of the transwell system. Seventy-two hours later the Jurkat cells were removed, afﬁxed to a microscope slide and stained for HIV-1 gp120 (Red), HTLV-1
Tax (Green) or DNA by DAPI (Blue). Yellow color in the merged panel indicates co-staining for both proteins.
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Env protein (Fig. 3B, lanes 3–5).
To test the infectivity of our ACH-Chimera virus, we generated
viral stocks by transfecting 293 T cells with 10 μg of pACH with
1 μg pCTax (CMV promoter-driven Tax) or 10 μg pACH-Chimera
with 1 μg pCTax. Seventy-two hours after transfection superna-
tants were harvested, ﬁltered, and HTLV-1 virus production was
determined by HTLV-1 p19 Gag Elisa (Zeptometrix, Buffalo, NY).
To characterize the ACH and ACH-Chimera viruses, we asked if we
could distinguish between the two viruses based on their envelope
proteins. Thus, we challenged ACH-virus or ACH-Chimera particles
with either HIV-1 or HTLV-1 neutralizing antibodies (Fig. 3C).
Accordingly, Jurkat T-cells were infected with p19 Gag-equivalent
amounts of either ACH WT or ACH Chimera in the presence of
neutralizing antibodies speciﬁc for HIV-1 or HTLV-1. Eight days
post infection the level of cell associated viral RNAwas determined
by quantitative RT-PCR of total cellular RNA, and we observed that
the ACH-virus was sensitive to HTLV-1 neutralizing antibody while
the ACH-Chimera was sensitive to HIV-1 neutralizing antibody,
consistent with the expression and function of HIV-1 Env
expressed from the latter genome (Fig. 3C).
We next determined the ability of the ACH-Chimera virus to
replicate in tissue culture. Jurkat T-cells were infected with ACH or
ACH-Chimera virus, normalized by HTLV-1 p19 Gag measure-
ments. RNA was extracted from infected cells at 4, 6, 8, 10, 12
and 14 days post infection, and HTLV-1 viral RNA was quantiﬁed
by q-RT-PCR (Fig. 3D). The results showed that both ACH andACH-Chimera were replication competent with the latter replicat-
ing approximately 0.5 to 1 log less well than the wild type ACH.
ACH-chimera suppresses HIV-1 replication
Previous ﬁndings suggest that homologous Env expression may
sufﬁciently mediate virus super infection exclusion. As an addi-
tional functional test, we asked if infection of Jurkat T-cells by
ACH-Chimera could elicit super infection exclusion of wild type
HIV-1. Jurkat T-cells were infected with equivalent amounts of
ACH or ACH-Chimera, as determined by p19 elisa. Four days after
infection, the cells were challenged with a second infection using
HIV-1 NL4-3. Supernatant was collected and assayed for the
presence of infectious HIV-1 particles by exposing the TZMbl
indicator cell line to culture supernatants and assaying for Tat
induced β-galactosidase expression (Fig. 3E). The read out from a
Tat responsive reporter allowed us to accurately measure and
segregate HIV-1 from HTLV-1 production. In repeated assays, prior
infection with ACH-Chimera compared to ACH consistently
reduced production of HIV-1 via a subsequent super infection.
This result is consistent with functional HIV-1 Env expression
from ACH-Chimera excluding super infection of the cells by
HIV-1 NL4-3.
We were intrigued that Env alone could be effective at blocking
infection. Env is thought to work in concert with Vpu and Nef to
down-regulate CD4 to block infection (Lindwasser et al., 2007;
Wildum et al., 2006). However, CD4 down-regulation occurs late
Fig. 2. HIV-1 may be pseudotyped by HTLV-I Env. Jurkat or MT2 cells were infected with mock supernatant or NL4-3 ΔEnv pseudotyped with VSV-G. Three days post
infection, cells were co-cultured with the HIV-1 indicator cell line TZMbl. One day after co-culture, infection with HIV-1 was detected by b β-galactosidase staining of the
TZMbl cells. (A) Representative micrographs of the four conditions. (B) Triplicate experiments were performed to determine the number of β-galactosidase positive TZMbl
cells following co-culture. (C) Infection of MT2 cells with mock or NL4-3 ΔEnv pseudotyped with VSV-G was performed as above. Co-culture was performed in the presence
of increasing concentrations of anti–anti-HIV-1 (VRC01) or anti-HTLV-1 neutralizing antibodies. nn p-value≤0.01, nnn p-value≤0.001.
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important for viral release (Arganaraz et al., 2003; Benson et al.,
1993; Nethe et al., 2005). Further, there is evidence that resistance
to super infection occurs early in infection and when CD4 levels
are still high (Saha et al., 1999; Volsky et al., 1996). This led us to
posit that Env might be blocking infection without altering CD4
expression; possibly by binding CD4 at the cell surface. To test this
hypothesis we transfected TZMbl with a GFP expression vector and
0.5 or 1 μg of Env expression vector. Twenty-four hours post
transfection the cells were infected with NL4-3 at an MOI of 0.2.
Twenty-four hours post infection the cells were imaged for GFP
and β-galactosidase expression. The number of β-gal (HIV-1
infected) cells per GFP positive (transfected cells) was then
determined (Supplemental Fig. S2A). Transfection of cells with
wild-type (WT) or fusion-peptide mutant (FP Mut) Env was
capable of reducing infection by NL4-3. However, a mutant
incapable of binding CD4 (BS Mut) did not mediate this effect.
Further, no down-regulation of CD4 was detected after transfec-
tion with wild-type Env (Supplemental Fig. S2B).Conclusions
Although there have been clear reports of patients co-infected
with both HIV-1 and HTLV-1, evidence for co-infection at the
cellular level is unclear (Bahia et al., 2011; Beilke, 2012; Pedroso
et al., 2011). Herein, we demonstrate de novo infection of HTLV-I
producing cells (MT2) by cell free infection with HIV-1. We further
demonstrate that co-infection of MT2 cells lead to pseudotyping of
HIV-1 with HTLV-1 envelope. Because HTLV-1 Env is thought tohave a broader tropism than HIV-1 Env, this ﬁnding suggests that
such pseudotyping could possibly lead to single round infection of
non-classical target cells by HIV-1. Nevertheless, the biological
relevance of this observation to HIV-1 pathogenesis in dually co-
infected hosts remains unknown.
We next determined whether the reciprocal ﬁnding could be
shown (i.e. pseudotyping of HTLV-1 by HIV-1 Env). We created a
chimeric HTLV-1 virus that substituted the HIV-1 Env for its own
envelope protein. This virus expresses the HIV-1 envelope and is
competent for a spreading infection in a T-cell line (Fig. 3).
Furthermore, infection with the chimeric HTLV-1 (ACH-Chimera)
virus altered the replication of a subsequent HIV-1 infection. The
above observation suggests that envelope expression-alone is
sufﬁcient to mediate super infection exclusion. It raises the
possibility that pathologically attenuated HTLV-1 vector that
replicates using an HIV-1 Env could be a gene-based strategy
against HIV-1 infection.Methods
Cell culture and transfections
Adherent cell lines (TZMbl and 293 T) were maintained in
DMEM supplemented with 10% fetal bovine serum, L-glutamine
and penicillin/streptomycin. Adherent cell lines were transfected
using Lipofectamine LTX (Invitrogen) according the manufacturer's
protocol. Suspension cell lines (Jurkat, J-LTR-G and MT2) were
maintained in RPMI supplemented with 10% fetal bovine serum,
L-glutamine and penicillin/streptomycin.
Fig. 3. Construction and characterization of a chimeric Env and chimeric HTLV-1 molecular clone. (A) Signal peptide from HTLV-I Env (top panel) was fused to the HIV-1 Env
sequence (middle panel) to create a chimeric Env (bottom panel) which was then transferred back into the pACH molecular clone by way of the SphI and NsiI sites. This
process results in the preservation of HTLV-I splicing sequences and perturbs no viral genes apart from the Env. (B) Western blot analysis of expression of HIV-1 Env after
transfection of seeded 2105 TZMbl cells with 0, 0.25, 0.5 or 1 μg of pACH or pACH-Chimera. Arrows indicate gp160 and gp120. Extracts were used to blot for β-actin to
insure equal loading. (C) 5104 Jurkat T-cells were seeded in each well of a 96 well plate and infected with ACH or ACH-Chimera in the presence of αHIV-1 nAb (1:100) or
αHTLV-1 nAb (1:200). Eight days post-infection RNA was isolated from the cells and used to determine relative infection by qPCR for HTLV-1 Gag. n p-value≤0.05,
nn p-value≤0.01, nnn p-value≤0.001 (D) 6106 Jurkat T-cells were infected with equal amounts of ACH or ACH-Chimera molecular clones as determined by p19 Elisa. RNA was
extracted from infected cells at days 4, 6, 8, 10, 12 and 14 post infection. Quantitative RT-PCR was used to determine the expression of HTLV-1 Gag mRNA as compared to
cellular GAPDH mRNA. (E) ACH or Chimera infected Jurkat T-cells from day 4 of infection were exposed to equal quantities of NL4-3 HIV-1 molecular clone. Supernatant was
harvested at days 2, 4, 6 and 8 post infection. HIV-1 replication was determined by measuring infectious units per ml of culture media in TZMbl cells.
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Infection of J-LTR-G cells was followed by ﬂow cytometry. Cells
were stained using anti-gp46 antibody (Abcam) for one hour,
washed and then stained with anti-mouse AlexaFluor647 (Invitro-
gen). Staining for cell surface gp46 and GFP expression was
detected using a Becton Dickinson Fortessa LSR.
Fluorescent microscopy
Jurkat cells were afﬁxed to a positively charged glass slide
through use of a CytoSpin and ﬁxed with 1% paraformaldehyde
for 10 min. Cells were then washed, blocked in PBS with 1% BSA
and 0.1% NP40 and stained with goat anti-gp120 (1:500) (AbCam)
or mouse anti-Tax hybridoma supernatant (1:200). After another
series of washes, the cells were stained with anti-goat antibody
conjugated to AlexaFluor594 (1:1000) (Invitrogen) and anti-mouse
AlexaFluor488 (1:1000) (Invitrogen). Cells were then washed,
stained with DAPI and imaged use a ﬂuorescent microscope.
Infection and neutralization assays
TZMbl cells were used to determine infection via HIV-1 (either
WT or pseudotyped). Cells were incubated with cell free virus or
co-cultured with source cells for 24h. After incubation with virus,
the cells were ﬁxed and stained for expression of β-galactosidase
ﬂuorescently using the ImaGeneRed LacZ kit (Invitrogen). For
neutralization assays, cells were incubated with anti-HIV-1
VRC01 or anti-HTLV-1 antiserum (AIDS Reagent Program) con-
comitantly with infecting virus. Final dilutions of antibody were
1:100, 1:200 or 1:1000 as indicated.
Viral infections
HIV-1 viral stocks were generated by transfecting the proviral
plasmid pNL4-into 293 T cells. Seventy-two hours after transfection,the culture supernatant was clariﬁed by centrifugation and ﬁltered
using a 0.22 mM ﬁlter to remove remaining cells. Viral stocks were
quantiﬁed using reverse transcriptase assay and titered on TZMbl
cells. Infection of TZMbl cells was determined by β-galactosidase
staining and replication in Jurkat T-cells was followed by reverse
transcriptase assay.
HTLV-1 viral stocks were generated by transfecting 293 T with
pACH proviral plasmid and pCMV-Tax at a ratio of 10:1. Seventy-
two hours after transfection the culture supernatant was clariﬁed
by centrifugation, ﬁltered using a 0.22 mM ﬁlter to remove remain-
ing cells and concentrated by ultracentrifugation. Viral stocks were
quantiﬁed using p19 Elisa (Zeptometrix). For cell free infection,
6106 Jurkat cells were incubated with HTLV-1 viral stock
containing 10 ng p19 in 2 ml media for 16 h. Infected cells were
then washed and re-suspended in media at 1106 cells/ml.
Infection was followed by extracting cell associated RNA from
the cells every other day and virus replication was detected by
qPCR for HTLV-1 GagConstruction of chimeric HTLV-1
The leader peptide of HTLV-1 Env was PCR ampliﬁed from the
X1MT HTLV-1 molecular clone using primers X1MT 5226 F and
HTLV Env ExtR. The HTLV Env Ext R primer contains sequence
matching the desired junction with the HIV-1 envelope and the
KpnI site found in the HIV-1 Envelope. Ampliﬁed HTLV-1 leader
peptide plus adapter was digested with SphI and KpnI and ligated
into the SphI and KpnI sites of pUC19 to created pUC-3′HTLVEnv.
A fragment of the HIV-1 Env was ampliﬁed from pNL4-3 using
HIV Env F and HIV 8785 EcoRI R primers. The resulting PCR
fragment was digested with KpnI and EcoRI and ligated into the
KpnI and EcoRI sites of pUC-3′HTLVEnv. The complete envelope
containing fragment was then ampliﬁed by PCR using primers
Chim PstI and Chim R (below). Fragment was digested using SphI
and PstI and ligated into pACH using the SphI and NsiI sites.
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HTLV Gag Rev CAAGCCCGCAACATATCTCC
X1MT 5226 F ATAGCCGCCAGTGGAAAGGACC
HTLV Env Ext R CAGGTACCCCATAATAGACTGTGACCCA-
CAATTTTTCTGTACCGAGGATGAGG-
GGGCAGHIV Env F CTGCCCCCTCATCCTCGGTACA-
GAAAAATTGTGGGTCACChim PstI CTGCAGAAAACGACGGCCAGTG
Chim R ATGCTTCCGGCTCGTATGAppendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.04.027.References
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